A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This randomized, open-label, two-way crossover study will evaluate the relative bioavailabilty and safety of capecitabine rapid disintegrating tablets (RDT) versus commercial Xeloda tablets in patients with colorectal or breast cancer. Patients will be randomized to a sequence of single oral doses of capecitabine RDT or Xeloda on Days 1 and 2 of a 14-day treatment cycle with Xeloda. Follow-up will be 30 days.
A Randomized, Open-label, Single Dose, Two-way Cross-Over Study to Investigate the Relative Bioavailability of Capecitabine in Rapid Disintegrating Tablets (RDT) Versus the Commercial Xeloda® Tablets Following Oral Administrations in Adult Patients With Solid Tumours
Study Start Date
Actual Primary Completion Date
Actual Study Completion Date
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Adult patients,>/= 18 years of age
Histological/cytological confirmation of colorectal or breast cancer
Patient is ambulatory and has a Karnofsky performance status of > 70%
Body surface area between 1.5 and 2.0 m2
Due to receive Xeloda as monotherapy or as combination therapy as per their treating physician's treatment plan, or
Currently receiving Xeloda monotherapy and in the investigator's opinion able to tolerate study drug dose on Day 1 and Day 2
Any contraindication to Xeloda
Received Xeloda in the 6 days prior to Day 1
Subjects with organ allografts (other than autologous bone marrow transplant after high dose chemotherapy)
Pregnant or lactating females
Participation in an investigational drug study within 28 days prior to screening
Lack of physical integrity of the upper gastrointestinal tract, or clinically significant malabsorption syndrome
Serious uncontrolled intercurrent infections
History of clinically significant coronary artery disease